RT Journal Article SR Electronic T1 Safer Prescribing and Care for the Elderly (SPACE): a pilot study in general practice JF BJGP Open JO BJGP Open FD Royal College of General Practitioners SP bjgpopen18X101594 DO 10.3399/bjgpopen18X101594 VO 2 IS 3 A1 Katharine A Wallis A1 C Raina Elley A1 Simon Moyes A1 Ngaire Kerse YR 2018 UL http://bjgpopen.org/content/2/3/bjgpopen18X101594.abstract AB Background High-risk prescribing places patients at increased risk of adverse drug events (ADEs). High-risk prescribing and ADE hospitalisations are increasingly common as people are living longer and taking more medicines for multiple chronic conditions. The Safer Prescribing and Care for the Elderly (SPACE) intervention is designed to foster patient engagement in medicines management and prompt medicines review.Aim To pilot the SPACE intervention in preparation for a larger cluster randomised controlled trial (RCT).Design & setting A pilot study in two general practices. Study participants were all patients at increased risk of an adverse drug reaction (ADE) from non-steroidal anti-inflammatory drugs (NSAIDs) and/or antiplatelet medicines. The primary outcome was the proportion of participants receiving high-risk prescribing at 6 months and 12 months compared with baseline.Method The SPACE intervention comprised automated practice audit to identify and generate for each GP a list of patients with high-risk prescribing for these medicines; an outreach visit by clinical advisory pharmacist to deliver education and to go through with each GP their list of at-risk patients and indicate in a tick-box the intended action for each patient; and a mail-out from GPs to selected patients containing a medicines information brochure and a letter encouraging patients to discuss their medicines when they next see their GP.Results SPACE can be delivered within existing primary care infrastructure. The rate of high-risk prescribing was reduced at 6 months following the delivery of the intervention, but these improvements were not evident at 12 months.Conclusion SPACE prompts medicines review and shows promising signs of supporting safer prescribing in general practice in the short term. A randomised trial of SPACE started in 2018.